AZ’s COPD triple therapy approved in the USAstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the Share XAZ’s COPD triple therapy approved in the UShttps://pharmaphorum.com/news/azs-copd-triple-therapy-approved-in-the-us/
UK pharma resilient in 2Q, despite pandemic falloutUK manufacturing exports fell sharply during the second quarter as the COVID-19 pandemic gathered pace, but pharma and Share XUK pharma resilient in 2Q, despite pandemic fallouthttps://pharmaphorum.com/news/uk-pharma-resilient-in-2q-despite-pandemic-fallout/
FDA approves Jazz Pharmaceuticals’ narcolepsy therapyThe FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy, Share XFDA approves Jazz Pharmaceuticals’ narcolepsy therapyhttps://pharmaphorum.com/news/fda-approves-jazz-pharmaceuticals-narcolepsy-therapy/
Healthware launches global resource hub for COVID-19’s ‘new normal’Healthware has launched a new online resource that aggregates information and analysis on how to respond to the Share XHealthware launches global resource hub for COVID-19’s ‘new normal’https://pharmaphorum.com/news/healthware-resource-covid-19-new-normal/
Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analystJP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high Share XModerna’s $37B market cap is too high, despite COVID-19 vaccine; analysthttps://pharmaphorum.com/news/modernas-37b-market-cap-is-too-high-despite-covid-19-vaccine-analyst/
Inozyme plans $75m IPO as it heads for clinic with rare bone diseases drugUS biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a Share XInozyme plans $75m IPO as it heads for clinic with rare bone diseases drughttps://pharmaphorum.com/news/inozyme-plans-75-ipo-as-it-heads-for-clinic-with-rare-bone-diseases-drug/
Jo Spadaccino joins healthcare comms agency ZPB as a partnerPR agency ZPB has appointed Jo Spadaccino as a partner to help realise its ambition of offering an Share XJo Spadaccino joins healthcare comms agency ZPB as a partnerhttps://pharmaphorum.com/news/jo-spadaccino-zpb-pharma/
Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOAfter more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down Share XEx-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOhttps://pharmaphorum.com/news/ex-taris-ceo-tony-kingsley-claims-tenure-as-scholar-rocks-new-ceo/
J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayThe FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share XJ&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayhttps://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/
Tom Richards joins 21GRAMS as co-global chief creative officerW2O advertising and marketing agency 21GRAMS has appointed Tom Richards as its co-global chief creative officer. He joins Share XTom Richards joins 21GRAMS as co-global chief creative officerhttps://pharmaphorum.com/news/tom-richards-w2o-21grams/
Syneos Health bolsters healthcare communications leadershipSyneos Health has made a series of senior appointments to the leadership of its communications business under new Share XSyneos Health bolsters healthcare communications leadershiphttps://pharmaphorum.com/news/syneos-health-cassidy-tender-dorrian/
LEO eyeing 2021 US launch for eczema drug tralokinumabLEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the Share XLEO eyeing 2021 US launch for eczema drug tralokinumabhttps://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
FDA grants fast review of AZ’s Brilinta to prevent recurring strokesThe FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce Share XFDA grants fast review of AZ’s Brilinta to prevent recurring strokeshttps://pharmaphorum.com/news/az-grants-fast-review-of-astrazenecas-cardiovascular-diseases-drug-brilinta/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Biogen shares pop as it completes filing for Alzheimer’s drug aducanumabBiogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Share XBiogen shares pop as it completes filing for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/
FCB Health’s Neon appoints Sebastian MallarinoSebastian Mallarino has joined FCB Health Network’s Neon agency as its group creative director. A native Colombian, he Share XFCB Health’s Neon appoints Sebastian Mallarinohttps://pharmaphorum.com/news/fcb-health-neon-sebastian-mallarino/
European Commission approves Gilead’s remdesivir for COVID-19The European Commission has conditionally approved Gilead’s remdesivir for treatment of COVID-19, the first drug officially cleared for use against Share XEuropean Commission approves Gilead’s remdesivir for COVID-19https://pharmaphorum.com/news/european-commission-approves-gileads-remdesivir-for-covid-19/
J&J’s Ebola vaccine approved in EUThe European Commission has approved Johnson & Johnson’s Ebola vaccine, developed by its Janssen pharmaceuticals unit and Bavarian Share XJ&J’s Ebola vaccine approved in EUhttps://pharmaphorum.com/news/jjs-ebola-vaccine-approved-in-eu/
